Efficacy and Safety of rhGH (Jintropin®) in Pediatric Participants With ISS

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
Phase 1: To evaluate the safety and efficacy of 0.05mg/kg/d of rhGH (Jintropin®) in the treatment of children with idiopathic short stature (ISS) in 52 weeks. Phase 2: To evaluate the safety and efficacy of rhGH (Jintropin®) in the treatment of children with ISS in 2 years
Epistemonikos ID: 2444a633f4a03366895d69c53ce342c088372070
First added on: May 21, 2024